Xilio Therapeutics, Inc.(XLO)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

Xilio Therapeutics, Inc. (XLO) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores XLO at 35.6/100 on a 32-signal composite quality model, placing it at rank #2,300 of 2,960 stocks — the bottom half of the AI-ranked universe. XLO scores in the top quartile across institutional flow (98.9), revenue growth (97.3). Areas of concern include earnings quality (1.3) and free cash flow (6.6), which score below median versus the broader universe. Shareholder dilution risk is elevated at 11.2/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Xilio Therapeutics, Inc. reports quarterly revenue of $18.7M, net income of $-6.4M, free cash flow of $-18.8M. Top institutional holders of XLO by reported 13-F value include Bain Capital Life Sciences Investors, GILEAD SCIENCES, ORBIMED ADVISORS, based on the most recent SEC filings. XLO trades on the Nasdaq exchange and files with the SEC under CIK 1840233. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate XLO daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Xilio Therapeutics, Inc. directly from SEC EDGAR.